CAR T-cell Therapies Sector to Grow Exponentially in Coming Years, States RNCOS in Its New Report Available at MarketPublishers.com24 Jan 2018 • by Natalie Aster
LONDON – Close to 15.2 million cancer incidences were registered as of 2015, with the number set to reach close to 19.3 million and 21.6 million by end-2025 and end-2030, respectively.
The various limitations and negative effects of traditional therapies have created a huge need for cancer treatment with therapies with improved efficacy and lesser side effects. T-cell immunotherapy is one of such novel therapies, which has had a promising future in the treatment of even advanced cancer.
T-cell immunotherapy is a fast evolving field of oncology. This therapy is aimed at overcoming the challenge of getting the proper type of T-cell to the targeted tumour cells. It uses patients’ own immune cells to fight against cancer. These immune cells are taken from the patient and genetically modified before they can be utilised for the treatment. Manifold researches are being carried out globally to investigate the potential of T-cell immunotherapy to treat versatile cancer types. During these research studies, T-cell immunotherapies have shown clinical trial successes on some accounts alongside several crucial issues on others. All in all, this therapy has turned out to be one of the innovative and powerful arms of the immunotherapeutic marketplace.
Chimeric antigen receptor (CAR) T-cell therapies are the most investigated treatment modality as they have demonstrated outstanding results in the course of clinical trials. The market for these T-cell immunotherapies is poised to expand exponentially on the back of the high VC investments and booming research activities in this domain.
New research report “Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis” elaborated by RNCOS E-Services offers an all-round, unbiased examination of the actual condition of the market worldwide.
The study highlights the prevalence rates of leading cancer types for which T-cell therapy is used, on a global and regional basis. It provides an extensive evaluation of the pipeline of T-cell immunotherapies, by phase, therapeutic indication, geographic area, vector used, technology, and dominant players. A list of the key ongoing clinical studies alongside their clinical phases by industry and research collaborations is included. The report discusses the leading players, like Novartis, Juno Therapeutics and Gilead Sciences, amid others, in the industry, giving a brief business overview, financial details, product portfolio, pipeline, latest developments and SWOT analysis of each of the players discussed. Furthermore, the study pinpoints the opportunity areas in the world T-cell immunotherapy marketplace.
Other new research reports by RNCOS E-Services are available at its page at MarketPublishers.com.